Wealth Enhancement Advisory Services
ESPR icon

Wealth Enhancement Advisory Services’s Esperion Therapeutics ESPR Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-12,321
Closed -$39.2K – 4292
2026
Q2 		$39.2K Sell
12,321
-11,647
-49% -$32.6K ﹤0.01% 3954
2026
Q1 		$62.6K Sell
23,968
-4,370
-15% -$13.8K ﹤0.01% 3402
2025
Q4 		$105K Buy
28,338
+4,422
+18% +$14.3K ﹤0.01% 3417
2025
Q3 		$73.9K Buy
23,916
+8,394
+54% +$16.2K ﹤0.01% 3376
2025
Q2 		$18.2K Buy
+15,522
New +$15.5K ﹤0.01% 3309
2024
Q4 		– Sell
-23,661
Closed -$39K – 2997
2024
Q3 		$39K Buy
23,661
+4,840
+26% +$9.77K ﹤0.01% 2637
2024
Q2 		$41.8K Buy
18,821
+7,100
+61% +$16.7K ﹤0.01% 2463
2024
Q1 		$31.4K Buy
+11,721
New +$28.5K ﹤0.01% 2368

Wealth Enhancement Advisory Services's ESPR Position: Q3 2026 in Review

Wealth Enhancement Advisory Services sold out of Esperion Therapeutics (ESPR) in Q3 2026, closing a stake of 12,321 shares — an estimated $39.2K sold.

Wealth Enhancement Advisory Services first reported a position in ESPR in Q1 2024 and held it in 8 quarters. The position peaked at $105K in Q4 2025. 0 funds tracked by Wall St. Rank hold ESPR as of Q3 2026.

  • Wealth Enhancement Advisory Services reported no remaining Esperion Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Wealth Enhancement Advisory Services sold 12,321 Esperion Therapeutics shares in Q3 2026, an estimated $39.2K.
  • Wealth Enhancement Advisory Services first reported a position in Esperion Therapeutics in Q1 2024 and held it in 8 quarters.
  • Wealth Enhancement Advisory Services's Esperion Therapeutics position peaked at $105K in Q4 2025.
  • 0 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.